Marine Animals Are an Untapped Source of Blood Pressure-Lowering Peptides for Food and Drugs

Marine invertebrates contain peptides with demonstrated anti-hypertensive properties (primarily ACE inhibition), but the field needs more clinical research and standardized methods to translate these into pharmaceuticals and functional foods.

Walquist, Mari Johannessen et al.·Marine drugs·2024·Preliminary EvidenceReview
RPEP-09461ReviewPreliminary Evidence2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Preliminary Evidence
Sample
N=N/A (review)
Participants
Review of marine-derived anti-hypertensive peptides across species

What This Study Found

Marine invertebrates contain peptides with documented ACE-inhibitory and anti-hypertensive activity, but translation to human therapeutics requires more clinical studies and standardized assessment methods.

Key Numbers

Review covers peptides from various marine organisms; multiple mechanisms of anti-hypertensive action discussed.

How They Did This

Comprehensive review of anti-hypertensive peptides from marine invertebrate phyla, covering extraction methods, assessment techniques, in vitro and in vivo evidence.

Why This Research Matters

Marine environments contain vast biodiversity with therapeutic potential. Identifying anti-hypertensive peptides from sustainable marine sources could provide natural alternatives to synthetic blood pressure medications with fewer side effects.

The Bigger Picture

The ocean represents perhaps the largest untapped pharmacy on Earth. Marine-derived peptides for hypertension are just one example of how marine biodiversity could address major health challenges — if the science can catch up to the potential.

What This Study Doesn't Tell Us

Review highlights that most evidence is in vitro or animal-based. Diverse assessment methods complicate cross-study comparison. Many marine species remain unstudied. Sustainability of marine sourcing is a concern. Bioavailability of marine peptides after oral intake is uncertain.

Questions This Raises

  • ?Which marine peptides are most promising for clinical development as anti-hypertensive agents?
  • ?Can marine peptides be sustainably produced at scale through aquaculture or synthetic biology?
  • ?How does the bioavailability of marine peptides compare to food-derived terrestrial peptides?

Trust & Context

Key Stat:
Many species unexamined Marine invertebrates contain anti-hypertensive peptides but most species haven't been studied for therapeutic potential
Evidence Grade:
Preliminary to moderate evidence — abundant in vitro and animal data but very limited human clinical evidence. Translation to therapeutics is early-stage.
Study Age:
Published in 2024. Reflects the current state of marine pharmaceutical peptide research.
Original Title:
Marine-Derived Peptides with Anti-Hypertensive Properties: Prospects for Pharmaceuticals, Supplements, and Functional Food.
Published In:
Marine drugs, 22(4) (2024)
Database ID:
RPEP-09461

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Could seafood peptides lower blood pressure?

Research suggests yes — peptides extracted from marine animals like mussels, jellyfish, and sea cucumbers can inhibit ACE (the same enzyme targeted by blood pressure drugs like lisinopril). However, most evidence is from lab and animal studies. We don't yet know if eating marine foods delivers enough of these peptides to meaningfully lower blood pressure.

Why look to the ocean for blood pressure drugs?

Marine organisms have evolved unique peptides over millions of years. Some of these peptides can lower blood pressure through natural mechanisms with potentially fewer side effects than synthetic drugs. The ocean's vast biodiversity means there are likely many more therapeutic peptides waiting to be discovered.

Read More on RethinkPeptides

Cite This Study

RPEP-09461·https://rethinkpeptides.com/research/RPEP-09461

APA

Walquist, Mari Johannessen; Eilertsen, Karl-Erik; Elvevoll, Edel Oddny; Jensen, Ida-Johanne. (2024). Marine-Derived Peptides with Anti-Hypertensive Properties: Prospects for Pharmaceuticals, Supplements, and Functional Food.. Marine drugs, 22(4). https://doi.org/10.3390/md22040140

MLA

Walquist, Mari Johannessen, et al. "Marine-Derived Peptides with Anti-Hypertensive Properties: Prospects for Pharmaceuticals, Supplements, and Functional Food.." Marine drugs, 2024. https://doi.org/10.3390/md22040140

RethinkPeptides

RethinkPeptides Research Database. "Marine-Derived Peptides with Anti-Hypertensive Properties: P..." RPEP-09461. Retrieved from https://rethinkpeptides.com/research/walquist-2024-marinederived-peptides-with-antihypertensive

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.